POLE and cancer: At the same time, the rarity of mutations at catalytic residues in the exonuclease domain in cancers could reflect the fact that they do not prevent sliding of the primer terminus to the exonuclease site and, thus, do not provide Polε with the robustness needed to acquire the ultramutator phenotype.